Clinical Trials on Alzheimer Disease in Japan

Total 6962 results

AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Puerto Rico, Russian Federation, Serbia, South... and more
Remedy Pharmaceuticals, Inc.

Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction (CHARM)

Stroke, Acute | Brain Edema

United States, Spain, China, Italy, United Kingdom, Germany, Australia, Hungary, Taiwan, Israel, Canada, Portugal, Korea, Republic of, Czechia, Brazil, Switzerland, France, Belgium, Japan, Lithuania, Croatia, Denmark, Finland, Russian...
Amgen

Completed

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Poland, Switzerland, Korea, Republic of, Russian Federation, Hong Kong, Portugal, South Africa, Israel, Romania, Bulgaria, Greece, Australia, Sweden, Japan, Latvia and more
Hoffmann-La Roche

Active, not recruiting

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Non-Small Cell Lung Cancer

United States, Spain, Italy, Taiwan, Belgium, China, Hong Kong, Japan, Germany, Canada, Israel, Russian Federation, United Kingdom, France, Korea, Republic of, Poland, Netherlands, Ukraine, Romania, Australia, Hungary, Portugal
Novartis Pharmaceuticals

Terminated

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer (ATRACT-1)

Non-Small Cell Lung Cancer

United States, Greece, Hong Kong, Taiwan, Argentina, Germany, United Kingdom, Singapore, Italy, Spain, France, Korea, Republic of, Netherlands, Brazil, Canada, Turkey, China, New Zealand, Hungary, Poland, Australia, Japan, Israel, Bel... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

Poland, Romania, Ukraine, Chile, Canada, United States, Argentina, China, Czechia, Estonia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Norway, Peru, Russian Federation, Spain, Thailand, Turkey, United...
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Korea, Republic of, Japan, China, Lithuania, United States, Italy, Spain, Hungary, Israel, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Germany, Latvia, Mal... and more
La Jolla Pharmaceutical Company

Terminated

Study of LJP 394 in Lupus Patients With History of Renal Disease (ASPEN)

Lupus Erythematosus, Systemic | Lupus Nephritis

Taiwan, United States, Belarus, Serbia, Czech Republic, Philippines, Lebanon, India, Korea, Republic of, Argentina, Australia, Brazil, Bulgaria, Georgia, Germany, Hong Kong, Hungary, Indonesia, Italy, Malaysia, Mexico, Poland, Portugal and more
Daiichi Sankyo, Inc.

Completed

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)

Acute Myeloid Leukemia | Leukemia

Hong Kong, Canada, Belgium, France, Spain, Taiwan, United States, Australia, Czechia, Hungary, Italy, Israel, Japan, Korea, Republic of, Germany, China, Ukraine, Romania, Argentina, Croatia, Brazil, Serbia, Russian Federation, Portugal, Bulgari... and more
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom, Mexico
Pfizer

Completed

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

Chronic Pain | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Korea, Republic of, Taiwan, Australia, Serbia, Japan, New Zealand, Philippines, Lithuania, Russian Federation, Croatia, Brazil, Bulgaria, Slovakia, Colombia, Mexico, Peru, Ukraine
Novo Nordisk A/S

Active, not recruiting

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1)

Obesity

Finland, Spain, Taiwan, Korea, Republic of, United States, Netherlands, India, Japan, United Kingdom, Germany, Serbia, Denmark, Canada, Bulgaria, Australia, South Africa, Italy, Poland, Mexico, Belgium, Turkey, France, Argentina
Hospital Universitario Getafe

Completed

Third International Study on Mechanical Ventilation (ISMV)

Acute Respiratory Failure

United States, Netherlands, China, Colombia, Spain, Egypt, Canada, France, Australia, New Zealand, Argentina, Germany, India, Ecuador, Japan, Korea, Republic of, Uruguay, Bolivia, Brazil, Chile, Denmark, Greece, Hungary, Italy, Mexico, Mo... and more
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AstraZeneca
Daiichi Sankyo

Recruiting

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Breast Cancer

United States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Malaysia, Argentina, Hong... and more
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
Janssen Research & Development, LLC

Recruiting

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC)

Colitis, Ulcerative

United States, Denmark, Belgium, Austria, Greece, Korea, Republic of, United Kingdom, Israel, Poland, Japan, Italy, Germany, New Zealand, Australia, Spain, Norway, China, Taiwan, Switzerland, India, Brazil, Croatia, Netherlands, Estonia, Cana... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Esophageal Squamous Cell Carcinoma (ESCC) | Gastroesophageal Junction Carcinoma (GEJC) | Esophageal Adenocarcinoma (EAC)

China, Canada, United States, Argentina, Belgium, Brazil, Chile, Czechia, Denmark, Estonia, France, Germany, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Mexico, Peru, Philippines, Portugal, Romania, Russian Federation and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX)

Prostate Cancer

Romania, United States, Israel, Russian Federation, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Singapor... and more
Pfizer
Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd; Pierre Fabre Medicament

Completed

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)

BRAF V600E-mutant Metastatic Colorectal Cancer

United States, Spain, Korea, Republic of, United Kingdom, Australia, Czechia, Taiwan, Belgium, France, Hungary, Canada, Japan, Russian Federation, Netherlands, Israel, Germany, Turkey, Austria, Brazil, Poland, Italy, Argentina, Chile, Denmar... and more
Abivax S.A.

Recruiting

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Ulcerative Colitis

United States, Spain, Italy, Croatia, Israel, Japan, Romania, Belgium, New Zealand, India, Hungary, France, Poland, United Kingdom, Czechia, Mexico, Germany, Bulgaria, Brazil, Slovakia, Serbia, Lithuania, Argentina, Canada, Ireland
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, Bulgaria, Czechia, Hu... and more
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network for Gynaecological Oncological...

Active, not recruiting

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Endometrial Neoplasms

United States, Argentina, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Norway, Poland, Russian Federation, Spain, Sweden, Taiwan, T... and more
Eli Lilly and Company
Incyte Corporation

Terminated

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) (SLE-BRAVE-X)

Systemic Lupus Erythematosus

United States, China, France, Czechia, Taiwan, Hungary, Belgium, Australia, Korea, Republic of, Serbia, Mexico, Poland, Italy, United Kingdom, Germany, Spain, Japan, South Africa, Austria, Russian Federation, Israel, India, Argentina, Croati... and more
GlaxoSmithKline
Iqvia Pty Ltd

Recruiting

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (NIMBLE)

Asthma

United States, Australia, Austria, Canada, Finland, France, Germany, Ireland, Italy, Japan, Netherlands, Norway, Puerto Rico, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, Israel, Portugal
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Carcinoma, Non-squamous Non-small-cell Lung

Poland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
Pfizer
Astellas Pharma Inc

Active, not recruiting

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate Cancer

United States, Finland, China, France, Spain, Hungary, United Kingdom, Korea, Republic of, Canada, Czechia, Taiwan, Belgium, Australia, Argentina, Japan, Germany, India, Turkey, Slovakia, Russian Federation, Bulgaria, Italy, Ukraine, ... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Breast Cancer

Japan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
Novartis Pharmaceuticals

Completed

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)

Breast Cancer

United States, China, Belgium, Canada, France, Italy, Taiwan, United Kingdom, Hungary, Australia, Spain, Germany, Singapore, Austria, Japan, Israel, Russian Federation, Korea, Republic of, Thailand, Slovakia, South Africa, Switzer... and more
Boehringer Ingelheim

Active, not recruiting

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, Spain, China, Canada, Norway, Korea, Republic of, Taiwan, Belgium, Australia, Germany, Denmark, Singapore, Thailand, Italy, Japan, United Kingdom, Switzerland, Croatia, France, Netherlands, Malaysia, New Zealand, Arge... and more
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

Carcinoma, Non-Small-Cell Lung

United States, Denmark, Taiwan, China, Canada, Spain, Japan, Germany, United Kingdom, Brazil, India, Korea, Republic of, Australia, Italy, Norway, Israel, Greece, Turkey, Netherlands, Austria, Belgium, Hong Kong, Poland, Puerto Rico, Russian... and more
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

Lymphoma, Mantle-Cell

United States, China, Spain, Belgium, Canada, Australia, Czechia, Italy, Taiwan, Germany, Japan, New Zealand, United Kingdom, Denmark, Brazil, Israel, France, Netherlands, Korea, Republic of, Poland, Hungary, Austria, Switzerland, Por... and more
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
AstraZeneca

Recruiting

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)

Carcinoma, Non-Small-Cell Lung

United States, China, Korea, Republic of, Canada, Italy, Poland, Spain, Belgium, Netherlands, Japan, Germany, Brazil, Turkey, Russian Federation, United Kingdom, Greece, Israel, Australia, France, Puerto Rico
Eli Lilly and Company

Recruiting

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)

Breast Neoplasms | Neoplasm Metastasis

Japan, United States, China, Czechia, Belgium, Brazil, Germany, Netherlands, Russian Federation, Ukraine, Taiwan, France, Korea, Republic of, Italy, Spain, Australia, Turkey, India, Argentina, Greece, Austria, Mexico
Exelixis
Takeda; Roche-Genentech

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

Metastatic Prostate Cancer | Prostate Adenocarcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Russian Federation, Singapore, Spain, ... and more
Hoffmann-La Roche

Completed

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X)

Diabetic Macular Edema

United States, Korea, Republic of, United Kingdom, Brazil, Japan, Canada, Argentina, Australia, Austria, Denmark, France, Germany, Hungary, Italy, Poland, Slovakia, Spain, Singapore, Czechia, Hong Kong, Israel, Portugal, Russian Federation and more
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
Novartis Pharmaceuticals

Completed

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

Asthma

Germany, Belgium, India, Romania, South Africa, Croatia, Estonia, Russian Federation, Netherlands, Israel, Thailand, Lebanon, Canada, Philippines, Poland, Slovakia, United Kingdom, China, Latvia, Italy, Argentina, Greece, Mexico, Austria and more
Eli Lilly and Company

Completed

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis (RA-BEYOND)

Rheumatoid Arthritis

United States, Canada, Puerto Rico, China, Spain, Australia, Japan, India, Portugal, Germany, Turkey, Switzerland, Mexico, Poland, Belgium, France, Hungary, Korea, Republic of, Russian Federation, Taiwan, Israel, Austria, Italy, Argen... and more
AstraZeneca

Completed

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. (DELIVER)

Heart Failure With Preserved Ejection Fraction

United States, Canada, Belgium, Czechia, Hungary, Taiwan, Vietnam, Mexico, Peru, China, Japan, Bulgaria, Spain, Brazil, Saudi Arabia, Netherlands, Romania, Russian Federation, Poland, Argentina
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Breast Neoplasms

Korea, Republic of, Germany, United States, United Kingdom, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Greece, Guatemala, Hungary, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Phili... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966)

Biliary Tract Carcinoma

United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Spain, Taiwan, Thailand, Turkey, United Kingdom
MorphoSys AG

Active, not recruiting

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND)

Diffuse Large B-cell Lymphoma

Germany, France, Hungary, Italy, Spain, United States, Austria, Czechia, Australia, Israel, Korea, Republic of, Turkey, Taiwan, Argentina, Canada, Colombia, Ireland, Japan, Malaysia, New Zealand, Philippines, Poland, Romania, Russian... and more
Amgen
Zai Lab (China only)

Recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Canada, Japan, United States, Korea, Republic of, China, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Romania, Chile, Peru, Po... and more
Novartis Pharmaceuticals

Completed

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)

Myelogenous Leukemia, Chronic

South Africa, Italy, Belgium, Japan, Taiwan, Turkey, Canada, Germany, Spain, Egypt, United States, Singapore, Austria, France, Netherlands, Sweden, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Russian Federation, Brazil, Hungar... and more
Pfizer
Eli Lilly and Company; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co....

Recruiting

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Neoplasms

Canada, United States, Taiwan, Belgium, Korea, Republic of, Australia, China, Spain, New Zealand, Japan, Denmark, Germany, Netherlands, Italy, Russian Federation, Finland, Bulgaria, Czechia, India, Mexico, Slovakia, South Africa, Uk... and more
GlaxoSmithKline

Active, not recruiting

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Canada, Spain, Finland, Germany, Japan, Estonia, Belgium, South Africa, Korea, Republic of, Italy, Russian Federation, Australia, Mexico, United Kingdom, New Zealand, Poland

Clinical Trials on Alzheimer Disease in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations